EIP
VRTX icon

Epoch Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Epoch Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
446
-39
-8% -$17.3K ﹤0.01% 219
2026
Q1 		$217K Hold
485
– – ﹤0.01% 233
2025
Q4 		$220K Sell
485
-149
-24% -$64.2K ﹤0.01% 245
2025
Q3 		$248K Sell
634
-60,392
-99% -$25.2M ﹤0.01% 267
2025
Q2 		$27.2M Sell
61,026
-20,810
-25% -$9.59M 0.14% 171
2025
Q1 		$39.7M Sell
81,836
-4,641
-5% -$2.16M 0.21% 158
2024
Q4 		$34.8M Sell
86,477
-8,104
-9% -$3.76M 0.17% 171
2024
Q3 		$44M Sell
94,581
-91,448
-49% -$43.9M 0.2% 171
2024
Q2 		$87.2M Buy
186,029
+6,823
+4% +$2.96M 0.4% 88
2024
Q1 		$74.9M Sell
179,206
-179,710
-50% -$76M 0.33% 108
2023
Q4 		$146M Buy
358,916
+10,059
+3% +$3.72M 0.66% 36
2023
Q3 		$121M Sell
348,857
-18,587
-5% -$6.5M 0.77% 28
2023
Q2 		$129M Sell
367,444
-23,953
-6% -$8.07M 0.75% 32
2023
Q1 		$123M Buy
391,397
+54,198
+16% +$16.3M 0.73% 31
2022
Q4 		$97.4M Sell
337,199
-117,765
-26% -$35.9M 0.58% 51
2022
Q3 		$132M Sell
454,964
-46,972
-9% -$13.5M 0.86% 24
2022
Q2 		$141M Sell
501,936
-410,761
-45% -$110M 0.83% 28
2022
Q1 		$238M Buy
912,697
+92,849
+11% +$22M 1.17% 13
2021
Q4 		$180M Buy
819,848
+503,347
+159% +$97.9M 0.91% 23
2021
Q3 		$57.4M Buy
316,501
+95,729
+43% +$18.7M 0.32% 103
2021
Q2 		$44.5M Buy
+220,772
New +$46.2M 0.24% 129

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Epoch Investment Partners's VRTX Position: Q2 2026 in Review

Epoch Investment Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 8% in Q2 2026, selling an estimated $17.3K and leaving 446 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #219.

Epoch Investment Partners first reported a position in VRTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $238M in Q1 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Epoch Investment Partners held 446 shares of Vertex Pharmaceuticals worth $222K as of Q2 2026.
  • Epoch Investment Partners sold 39 Vertex Pharmaceuticals shares in Q2 2026, an estimated $17.3K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Epoch Investment Partners's portfolio in Q2 2026, its #219 holding.
  • Epoch Investment Partners first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Epoch Investment Partners's Vertex Pharmaceuticals position peaked at $238M in Q1 2022.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Epoch Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.